Article
Medicine, General & Internal
Maria Carla Gerra, Davide Carnevali, Paolo Ossola, Alberto Gonzalez-Villar, Inge Sokilde Pedersen, Yolanda Trinanes, Claudia Donnini, Matteo Manfredini, Lars Arendt-Nielsen, Maria Teresa Carrillo-de-la-Pena
Summary: This study explores DNA methylation differences in FM patients and healthy controls, identifying significant variations in the GCSAML region. The study also reveals distinct network structures of DNA methylation sites between the two groups, with the GRM2 region playing a central role in FM patients. Logistic regression analysis highlights the association between depressive symptoms, DNA methylation in the GRM2 region, and the risk of FM.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Psychiatry
Zarmina Islam, Adrijana D'Silva, Maitreyi Raman, Yasmin Nasser
Summary: Irritable bowel syndrome and fibromyalgia have similar pathophysiologic mechanisms and co-diagnosed patients experience more severe symptoms and decreased quality of life. Mind-body interventions, especially cognitive behavioral therapy and yoga, can improve patient-reported outcomes in both conditions individually.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Behavioral Sciences
Daniel F. Martins, Frederic J. F. Viseux, Daiana C. Salm, Anny Caroline Avelino Ribeiro, Helen Kassiana Lopes da Silva, Lynsey A. Seim, Edsel B. Bittencourt, Gianluca Bianco, Ari Ojeda Ocampo More, William R. Reed, Leidiane Mazzardo-Martins
Summary: Fibromyalgia syndrome is a common illness characterized by chronic widespread pain, sleep problems, fatigue, and cognitive difficulties. Dysfunctional neurotransmitter systems are thought to underlie many of the major FM-related symptoms. The vagus nerve has anti-inflammatory and psychological properties that may have therapeutic potential in treating FM.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2021)
Article
Clinical Neurology
Jean-Baptiste Quilichini, Alexis Revet, Philippe Garcia, Regis Bouquie, Jacques Hamard, Antoine Yrondi, Francois Montastruc
Summary: This study found that the use of short half-life antidepressants is associated with an increased risk of reporting withdrawal syndrome compared to long half-life antidepressants in patients. Especially for patients aged 18-44, women, and those treated with Paroxetine, Desvenlafaxine, Venlafaxine, and Duloxetine. These findings provide guidance for clinical practice.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Neurosciences
Anupam Sah, Maria Kharitonova, Katarzyna Mlyniec
Summary: Studies have shown that GPR39 knockout mice exhibit enhanced passive coping behavior, abnormal neuronal activity in specific brain regions, and resistance to traditional antidepressants. Imipramine partially reduces passive coping behavior by attenuating hyperactivity in the prefrontal cortex, but does not modulate abnormal brain activity in all regions. Antidepressant effects are suggested to be mediated through both GPR39-dependent and independent pathways in the brain.
Article
Psychology, Clinical
C. Gastaldon, E. Arzenton, E. Raschi, O. Spigset, D. Papola, G. Ostuzzi, U. Moretti, G. Trifiro, C. Barbui, G. Schoretsanitis
Summary: This study found that most antidepressants are associated with disproportionate reporting of neonatal withdrawal syndrome, which should be considered during pregnancy.
PSYCHOLOGICAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Atul Kabra, Ruchika Garg, James Brimson, Jelena Zivkovic, Saud Almawash, Muhammad Ayaz, Asif Nawaz, Syed Shams Ul Hassan, Simona Bungau
Summary: Depression is a condition that affects behavior and quality of life, and the effectiveness of conventional antidepressants is limited with various side effects. Therefore, researchers have turned to medicinal plants and their metabolites for potential treatments. Polyphenols, a class of compounds widely distributed in plants, have demonstrated antidepressant activity. Additionally, green nanoparticles synthesized from these medicinal plants have also shown potential efficacy in treating depression. These treatments work by regulating neuronal cell differentiation and apoptosis, promoting neuronal cell survival, and modulating key neurotransmitters.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Physiology
Mateus Dias Antunes, Amelia Pasqual Marques
Summary: Fibromyalgia is a chronic pain condition that significantly impacts the lives of patients. Physiotherapy has been shown to be an effective treatment method and can improve symptoms in individuals with fibromyalgia.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Medicine, General & Internal
Richard Berwick, Chris Barker, Andreas Goebel, Guideline Dev Grp
Summary: Fibromyalgia syndrome (FMS) is a common primary pain condition that affects the entire body, characterized by challenges in diagnosis due to lack of specific clinical laboratory investigations. Recent research has shown important evidence of changes in the central and peripheral nervous system functions, as well as immunological activity. The complexity of the condition, with fluctuating and multiple symptoms, makes it difficult for patients to articulate their symptoms and for healthcare professionals to fully understand the disease. The Royal College of Physicians' guidance aims to provide concise and relevant information to support clinicians in diagnosing FMS.
Article
Medicine, General & Internal
Raffaele Galiero, Teresa Salvatore, Roberta Ferrara, Francesco Masini, Alfredo Caturano, Giovanni Docimo, Margherita Borrelli, Luca Rinaldi, Giovanna Cuomo, Ferdinando Carlo Sasso
Summary: This study assessed the presence of small and large fiber impairment in fibromyalgic patients and found a high prevalence of neuropathic pain in these individuals.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Delia Bornand, Daphne Reinau, Susan S. Jick, Christoph R. Meier
Summary: This study explores the association between beta-blocker use and new-onset depression. The findings suggest that current short-term use of any beta-blocker is associated with an increased risk of developing depression, while long-term use is not. The elevated risk among short-term users is mainly observed in propranolol users with a neuropsychiatric disorder, indicating that the underlying indication may be a contributing factor to the onset of depression.
Review
Ophthalmology
Natalia Zdebik, Alexander Zdebik, Joanna Boguslawska, Joanna Przezdziecka-Dolyk, Anna Turno-Krecicka
Summary: Fibromyalgia is a chronic pain syndrome with unclear etiology, often associated with ocular symptoms and visual disturbances. Research suggests that changes in the eye may contribute to the pathogenesis of fibromyalgia, with corneal confocal bio-microscopy offering new possibilities for diagnostics and therapy. Further studies are needed to evaluate ocular involvement and potential ophthalmic examination modalities for fibromyalgia diagnostic criteria.
SURVEY OF OPHTHALMOLOGY
(2021)
Article
Psychology, Clinical
Rei Monden, Judith G. M. Rosmalen, Klaas J. Wardenaar, Francis Creed
Summary: This prospective population-based study assessed the predictors of new onsets of irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), and fibromyalgia (FM). The study found that syndrome-specific predictors were more common than shared ones. The study also revealed a close relationship between IBS and FM, which requires further research.
PSYCHOLOGICAL MEDICINE
(2022)
Article
Neurosciences
Satoshi Deyama, Katsuyuki Kaneda
Summary: The neurotrophic hypothesis of depression suggests that reduced levels of BDNF and VEGF are associated with depressive symptoms. Typical monoaminergic antidepressants can partially reverse these deficits by inducing the expression of BDNF and/or VEGF, but the effects are delayed. Ketamine, on the other hand, rapidly increases the release and/or expression of BDNF and VEGF, improving neuronal connectivity and neurogenesis, as well as leading to the sustained release of IGF-1, resulting in rapid and sustained antidepressant effects.
Article
Anesthesiology
Isabel Ellerbrock, Angelica Sandstrom, Jeanette Tour, Diana Kadetoff, Martin Schalling, Karin B. Jensen, Eva Kosek
Summary: The study investigated the impact of the OPRM1 gene polymorphism on symptom severity, pain sensitivity, and cerebral pain processing in fibromyalgia patients and healthy controls. G-allele carriers showed increased activation in the posterior cingulate cortex but decreased functional connectivity with the prefrontal cortex during pain stimulation, indicating differences in pain modulation processes between OPRM1 genotypes. Overall, the OPRM1 G-allele seems to have a stronger effect on fibromyalgia patients in terms of cerebral pain processing.
EUROPEAN JOURNAL OF PAIN
(2021)
